This ruling materially increases legal and regulatory risk for Eli Lilly in Michigan, removing a broad immunity defense. Traders should monitor the Ingham Circuit Court proceedings on remand for the court's determination on whether specific insulin pricing conduct is 'specifically authorized' by law. The ruling also signals potential for similar challenges in other states with consumer protection statutes, creating a broader overhang for pharmaceutical pricing models.
Price Chart
Executive Summary
The Michigan Supreme Court overruled two long-standing precedents (Smith and Liss) that had broadly exempted regulated industries from the Michigan Consumer Protection Act (MCPA). The ruling revives the Attorney General's investigation into Eli Lilly's insulin pricing practices, exposing the company to potential MCPA liability for its pricing of Humalog and Lispro. This is a material adverse legal development that removes a broad immunity defense for pharmaceutical and other regulated companies in Michigan, creating new litigation and settlement risk for Eli Lilly specifically.
Court Ruling Details
Key Facts
- The Michigan Supreme Court overruled Smith v Globe Life Ins Co (1999) and Liss v Lewiston-Richards, Inc (2007), which had broadly exempted regulated industries from the MCPA.
- The Court held that the MCPA exemption for 'transaction or conduct specifically authorized under laws administered by a regulatory board' must be narrowly applied to the specific conduct at issue, not the general transaction.
- The ruling reverses the Court of Appeals and vacates the circuit court order that had dismissed the Attorney General's complaint against Eli Lilly.
- The case is remanded to the Ingham Circuit Court to determine whether Eli Lilly's specific insulin pricing conduct is 'specifically authorized' by law.
- The Attorney General's investigation into Eli Lilly's pricing of Humalog and Lispro, including alleged violations of MCL 445.903(1)(z) (price gouging) and MCL 445.903(1)(i) (false representations), can now proceed.
- The circuit court had previously found probable cause to believe Eli Lilly violated the MCPA, a finding not challenged on appeal.
- The Court found that Smith and Liss had rendered the MCPA 'completely unworkable' and had been criticized as making Michigan's consumer protection law among the worst in the nation.
- The dissent argued the Attorney General lacked standing because no MCPA violation was actually pled, but the majority found a justiciable controversy existed due to the authorized investigative subpoenas.
Financial Impact
Eli Lilly faces renewed state-level investigation and potential MCPA liability for insulin pricing practices in Michigan. The ruling removes a broad regulatory exemption that had shielded pharmaceutical companies from MCPA claims. Financial exposure is not quantified in the ruling but could include civil fines, injunctive relief, and class-action damages if the investigation leads to enforcement.
Risk Factors
- Renewed state investigation and potential MCPA enforcement action in Michigan
- Potential for civil fines, injunctive relief, and class-action damages if violations are found
- Precedent could encourage similar challenges in other states with consumer protection laws
- Negative publicity and political pressure on insulin pricing practices
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 court opinion from CourtListener.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-46b25d0484-LLY |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 11, 2026 21d ago | Press Release | $1,115.70 $1,152.93 | ▲ +3.34% | ▲ +3.56% | $1,142.85 (+2.43%) |
Sep 8, 2026 24d ago | Court Ruling | $1,123.91 $1,138.28 | ▲ +1.28% | ▲ +1.94% | $1,142.85 (+1.69%) |
Aug 18, 2026 6w ago | Insider Cluster | $1,225.73 $1,233.66 | ▲ +0.65% | ▲ +0.85% | $1,142.85 (−6.76%) |
Aug 11, 2026 7w ago | Insider Cluster | $1,215.02 $1,225.73 | ▲ +0.88% | ▲ +1.29% | $1,142.85 (−5.94%) |
Aug 7, 2026 8w ago | Court Ruling | $1,185.71 $1,180.16 | ▼ −0.47% | ▼ −0.87% | $1,142.85 (−3.61%) |
Aug 5, 2026 8w ago | 8-K | $1,169.86 $1,220.28 | ▲ +4.31% | ▲ +3.96% | $1,142.85 (−2.31%) |
Aug 4, 2026 8w ago | Court Ruling | $1,115.68 $1,215.02 | ▲ +8.90% | ▲ +9.00% | $1,142.85 (+2.44%) |
Jul 31, 2026 9w ago | Court Ruling | $1,148.84 $1,185.71 | ▼ −3.21% | ▲ +0.30% | $1,142.85 (+0.52%) |
Jul 30, 2026 9w ago | Court Ruling | $1,154.97 $1,191.94 | ▲ +3.20% | ▼ −0.42% | $1,142.85 (−1.05%) |
Jul 22, 2026 10w ago | Press Release | $1,163.01 $1,210.02 | ▲ +4.04% | ▲ +6.44% | $1,142.85 (−1.73%) |
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more — parsed and scored by AI.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access